Sign In
Buy ETNB
$14.84
+0 (+0%)
At Close: Jan 29, 2026
89bio price target lowered by $8 at H.C. Wainwright, here's why
11:16am, Friday, 28'th Feb 2025
13 Nov 29 Jan
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
04:05pm, Thursday, 27'th Feb 2025
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to
Should You Buy 89BIO (ETNB) After Golden Cross?
10:55am, Thursday, 20'th Feb 2025
89BIO (ETNB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ETNB's 50-day simple moving average crossed above its 200-day si
Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High?
10:55am, Thursday, 20'th Feb 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 171.4% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positiv
Insider Buying Surges in February, Especially in These 6 Stocks
08:45am, Sunday, 09'th Feb 2025
In January, the number of notable insider purchases was somewhat muted.
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 06'th Feb 2025
SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercializat
Wall Street Analysts Think 89BIO (ETNB) Could Surge 219.06%: Read This Before Placing a Bet
10:55am, Monday, 03'rd Feb 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 219.1% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positiv
89bio's Pegozafermin Is Now Gaining Momentum
06:05am, Thursday, 30'th Jan 2025
89bio's Pegozafermin Is Now Gaining Momentum
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
10:31pm, Tuesday, 28'th Jan 2025
SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative the
Why 89bio Stock Lagged the Market Today
04:59pm, Tuesday, 28'th Jan 2025
89bio (ETNB 0.11%) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of the clinical-stage biotech, following news that it was floating a new sto
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
04:12pm, Monday, 27'th Jan 2025
SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative the
89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward
06:08pm, Monday, 13'th Jan 2025
89bio, Inc. results from the phase 3 ENTRUST study using pegozafermin for the treatment of patients with Severe Hypertriglyceridemia are expected in the 2nd half of 2025. Prior data from the phase 2 E
New Strong Sell Stocks for January 7th
04:26am, Tuesday, 07'th Jan 2025
ETNB, ATUS and ASH have been added to the Zacks Rank #5 (Strong Sell) List on January 7, 2024.
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 19'th Dec 2024
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercializat
New Strong Sell Stocks for November 16th
07:01am, Monday, 16'th Dec 2024
CLF, ETNB and HZO have been added to the Zacks Rank #5 (Strong Sell) List on November 16, 2024.
